Medicare Enrolled

Dr. Farid Razavi, M.D.

Gastroenterology · Wyomissing, PA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
1011 REED AVE, Wyomissing, PA 19610
6103744401
In practice since 2009 (17 years)
NPI: 1407099112 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Razavi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Razavi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Razavi

Dr. Farid Razavi is a gastroenterology specialist in Wyomissing, PA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Razavi performed 722 Medicare services across 674 unique beneficiaries.

Between the years covered by Open Payments, Dr. Razavi received a total of $108,057 from 46 pharmaceutical and/or device companies across 578 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Razavi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 28% volume in PA $108,057 industry payments

Medicare Practice Summary

Medicare Utilization ↗
722
Medicare services
Top 28% in PA for gastroenterology
674
Unique beneficiaries
$109
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~42 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
115 $65 $185
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
104 $95 $270
Upper GI endoscopy with biopsy
A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities.
94 $88 $645
Colon polyp removal with endoscopic snare
This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination.
84 $203 $1,025
Colonoscopy with biopsy
A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease.
49 $143 $875
Colonoscopy for colorectal cancer screening, high risk
A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease.
46 $176 $750
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
39 $121 $410
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
30 $101 $240
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
28 $61 $120
Upper endoscopy (EGD)
A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope.
25 $71 $530
Colonoscopy for colorectal cancer screening
A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease.
23 $175 $750
Colonoscopy
A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon.
20 $124 $750
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
18 $45 $120
Complete ultrasound of abdomen
A diagnostic imaging test that uses sound waves to create detailed pictures of the organs and structures within the abdomen.
16 $50 $350
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
16 $86 $270
Hospital follow-up visit, low complexity
Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service.
15 $39 $85
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$108,057
Total received (2018-2024)
Avg $15,437/year across 7 years
Top 3% in PA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
578
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$90,845 (84.1%)
Financial / Ownership
Ownership or investment interests, royalties, and licensing fees
$11,250 (10.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,962 (5.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$61,839
2023
$7,201
2022
$16,958
2021
$8,883
2020
$6,503
2019
$4,420
2018
$2,253

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Phathom Pharmaceuticals, Inc.
$51,974
ABBVIE INC.
$8,621
Janssen Biotech, Inc.
$203
Lilly USA, LLC
$143
Celgene Corporation
$116
GENZYME CORPORATION
$112
PFIZER INC.
$85
Ardelyx, Inc.
$83
Intercept Pharmaceuticals, Inc.
$66
Takeda Pharmaceuticals U.S.A., Inc.
$61
Madrigal Pharmaceuticals
$58
ORPHALAN INC
$53
Ipsen Biopharmaceuticals, Inc
$46
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$35
Digestive Care, Inc.
$34
Micro-tech Endoscopy USA, Inc.
$24
Mallinckrodt Hospital Products Inc.
$24
E.R. Squibb & Sons, L.L.C.
$22
Medtronic, Inc.
$20
Daiichi Sankyo Inc.
$16
AIMMUNE THERAPEUTICS, INC.
$15
Merck Sharp & Dohme LLC
$14
IRONWOOD PHARMACEUTICALS, INC
$14
Top 3 companies account for 98.3% of 2024 payments
All-time payments by company (2018-2024) ›
Phathom Pharmaceuticals, Inc.
$51,974
ABBVIE INC.
$19,680
AbbVie Inc.
$14,539
BioHorizons Implant Systems Inc.
$11,250
Allergan Inc.
$4,651
Janssen Biotech, Inc.
$967
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$732
Celgene Corporation
$641
AbbVie, Inc.
$423
Takeda Pharmaceuticals U.S.A., Inc.
$398
PFIZER INC.
$346
GENZYME CORPORATION
$322
Gilead Sciences, Inc.
$279
Medtronic USA, Inc.
$163
Lilly USA, LLC
$143
Ardelyx, Inc.
$137
QOL Medical, LLC
$109
Intercept Pharmaceuticals, Inc.
$106
Ironwood Pharmaceuticals, Inc
$101
UCB, Inc.
$97
Daiichi Sankyo Inc.
$85
Ferring Pharmaceuticals Inc.
$82
Synergy Pharmaceuticals Inc
$79
INTERCEPT PHARMACEUTICALS, INC.
$74
Madrigal Pharmaceuticals
$58
Regeneron Healthcare Solutions, Inc.
$55
ORPHALAN INC
$53
BOSTON SCIENTIFIC CORPORATION
$46
Ipsen Biopharmaceuticals, Inc
$46
RedHill Biopharma Inc.
$39
Nestle HealthCare Nutrition Inc.
$37
Medtronic, Inc.
$36
Digestive Care, Inc.
$34
Endo Pharmaceuticals Inc.
$33
Shionogi Inc
$33
Braintree Laboratories, Inc.
$27
Alexion Pharmaceuticals, Inc.
$25
Micro-tech Endoscopy USA, Inc.
$24
Mallinckrodt Hospital Products Inc.
$24
E.R. Squibb & Sons, L.L.C.
$22
NESTLE HEALTHCARE NUTRITION INC.
$17
AIMMUNE THERAPEUTICS, INC.
$15
Merck Sharp & Dohme LLC
$14
IRONWOOD PHARMACEUTICALS, INC
$14
Prometheus Laboratories Inc.
$13
Merck Sharp & Dohme Corporation
$12
Top 3 companies account for 79.8% of all-time payments
Associated products mentioned in payments ›
Amitiza · BIOHORIZONS · CAPTIVATOR COLD · CIMZIA · CREON · CUVRIOR · Cimzia · Creon · DIFICID · DUPIXENT · Dexilant · ENTYVIO · GATTEX · HUMIRA · Humira · IBSRELA · INJECTAFER · INTERSTIM · IQIRVO · LINZESS · Linzess · MAVYRET · Mavyret · Motegrity · Mulpleta · NASCOBAL · OCALIVA · OMVOH · Pertzye · REBYOTA · RELISTOR ORAL · REMICADE · RESMETIROM · RINVOQ · Rapide Balloons · SKYRIZI · STELARA · SUCRAID · SUTAB · Sucraid · TERLIVAZ · TREMFYA · TRULANCE · Talicia · Trulance · UCERIS · VIBERZI · VOQUEZNA · XELJANZ · XIFAXAN · XIFAXANIBSD · ZENPEP · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in gastroenterology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for gastroenterology in PA.

Looking for a gastroenterology specialist in Wyomissing?
Compare gastroenterologists in the Wyomissing area by procedure volume, costs, and industry payment transparency.
Browse gastroenterologists nearby

Geographic Context

Gastroenterologists within 10 mi
39
Per 100K population
9.1
County median income
$77,684
Nearest hospital
SURGICAL INSTITUTE OF READING
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Razavi is a clinical cardiology specialist, with above-average Medicare volume (top 28% in PA), with speaking/promotional industry engagement in the top 3% of PA peers, with 17 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Razavi experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Razavi performed 115 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Razavi receive payments from pharmaceutical companies?
Yes. Dr. Razavi received a total of $108,057 from 46 companies across 578 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Razavi's costs compare to other gastroenterologists in Wyomissing?
Dr. Razavi's average Medicare payment per service is $109. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Razavi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →